SCHEMBL23645356

SCHEMBL23645356

CCOC(=O)c1cc2n(n1)CCC(O)CO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.39
TDP1 Q9NUW8 1/20 0.39
PDE5A O76074 1/20 0.39
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 3/20 0.36
POLB P06746 1/20 0.36
PIK3CA P42336 1/20 0.36
JMJD6 Q6NYC1 1/20 0.36
MAPT P10636 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23645447 0.82 KMT2A (0.40) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL5848830 0.82 CYP1A2 (0.41) KMT2AGAAKDM4EPOLBPIK3CA
SCHEMBL23645383 0.80 KMT2A (0.39) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL19299941 0.80 KMT2A (0.41) FAAHKMT2AGAAKDM4EPIK3CA
SCHEMBL3548683 0.80 NPC1 (0.39) FAAHKMT2AGAAKDM4EPIK3CA
SCHEMBL19284267 0.79 KMT2A (0.40) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL19299854 0.79 KMT2A (0.40) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL19299890 0.79 KMT2A (0.40) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL13118705 0.79 CYP1A2 (0.42) FAAHKMT2AGAAKDM4EPOLB
SCHEMBL23645428 0.79 RAB9A (0.41) FAAHKMT2AGAAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2025-09-23 US disclosed
CN-112689636-B Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same 科研制药株式会社 2024-08-20 CN disclosed
EP-3851436-B1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2024-06-12 EP disclosed
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 US disclosed
EP-3851436-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2021-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A FAAH 435/4885TDP1 4006/4885PDE5A 2980/4885
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A FAAH 329/4885TDP1 3952/4885PDE5A 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.